CLSD Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 mai 2024 @ 22:00):

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space...

Stats
Dagens volum	182 482
Gjennomsnittsvolum	379 738
Markedsverdi	99.39M
EPS	$0 ( 2024-05-09 )
Neste inntjeningsdato	( $-0.140 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.42
ATR14	$0.00900 (0.68%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-15	Yerxa Benjamin R	Buy	7 813	Common Stock
2024-04-18	Gibney Anthony S	Buy	93 290	Common Stock
2024-04-17	Gibney Anthony S	Buy	6 710	Common Stock
2024-04-15	Gibney Anthony S	Buy	45 000	Stock Option (right to buy)
2024-04-15	Gibney Anthony S	Buy	0

INSIDER POWER
67.80
Last 97 transactions
Buy: 5 503 181 \| Sell: 2 142 358

Volum Korrelasjon

Lang: -0.15 (neutral)

Kort: 0.00 (neutral)

Signal:(50.988) Neutral

Clearside Biomedical Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Clearside Biomedical Inc Korrelasjon - Valuta/Råvare

0.30
( neutral )

0.24
( neutral )

0.00
( neutral )

0.27
( neutral )

0.00
( neutral )

-0.36
( neutral )

Clearside Biomedical Inc Økonomi

Annual	2023
Omsetning:	$8.23M
Bruttogevinst:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2023
Omsetning:	$8.23M
Bruttogevinst:	$7.80M (94.87 %)
EPS:	$-0.530

FY	2022
Omsetning:	$1.33M
Bruttogevinst:	$1.12M (84.63 %)
EPS:	$-0.570

FY	2021
Omsetning:	$29.58M
Bruttogevinst:	$29.58M (100.00 %)
EPS:	$0.00632

Financial Reports:

No articles found.

Clearside Biomedical Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Clearside Biomedical Inc

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.